Singapore markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
284.74+7.96 (+2.88%)
At close: 04:00PM EDT
288.75 +4.01 (+1.41%)
Pre-market: 09:08AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 70.98B
Enterprise value 62.58B
Trailing P/E 22.41
Forward P/E 17.86
PEG Ratio (5 yr expected) 0.38
Price/sales (ttm)8.56
Price/book (mrq)5.95
Enterprise value/revenue 7.49
Enterprise value/EBITDA 15.15

Trading information

Stock price history

Beta (5Y monthly) 0.45
52-week change 356.26%
S&P500 52-week change 3-16.34%
52-week high 3305.95
52-week low 3176.36
50-day moving average 3286.91
200-day moving average 3260.51

Share statistics

Avg vol (3-month) 31.38M
Avg vol (10-day) 31.43M
Shares outstanding 5256.46M
Implied shares outstanding 6N/A
Float 8255.86M
% held by insiders 10.23%
% held by institutions 194.66%
Shares short (30 Aug 2022) 42.83M
Short ratio (30 Aug 2022) 42.18
Short % of float (30 Aug 2022) 41.10%
Short % of shares outstanding (30 Aug 2022) 41.10%
Shares short (prior month 28 Jul 2022) 43.42M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 323 Aug 2000

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin 38.26%
Operating margin (ttm)37.59%

Management effectiveness

Return on assets (ttm)14.11%
Return on equity (ttm)30.24%

Income statement

Revenue (ttm)8.35B
Revenue per share (ttm)32.64
Quarterly revenue growth (yoy)22.50%
Gross profit (ttm)3.62B
EBITDA 3.28B
Net income avi to common (ttm)3.19B
Diluted EPS (ttm)12.23
Quarterly earnings growth (yoy)1,109.70%

Balance sheet

Total cash (mrq)9.25B
Total cash per share (mrq)36.08
Total debt (mrq)847.3M
Total debt/equity (mrq)7.10
Current ratio (mrq)4.50
Book value per share (mrq)46.61

Cash flow statement

Operating cash flow (ttm)4.02B
Levered free cash flow (ttm)2.52B